Cargando…
Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use
As of February 29, 2020, more than 85,000 cases of coronavirus disease 2019 (COVID-19) have been reported from China and 53 other countries with 2,924 deaths. On January 30, 2020, the first laboratory-confirmed case of COVID was reported from Kerala, India. In view of the earlier evidence about effe...
Autores principales: | Bhatnagar, Tarun, Murhekar, Manoj V., Soneja, Manish, Gupta, Nivedita, Giri, Sidhartha, Wig, Naveet, Gangakhedkar, Raman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288773/ https://www.ncbi.nlm.nih.gov/pubmed/32362644 http://dx.doi.org/10.4103/ijmr.IJMR_502_20 |
Ejemplares similares
-
Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020
por: Gupta, Nivedita, et al.
Publicado: (2020) -
Strategic planning to augment the testing capacity for COVID-19 in India
por: Gupta, Nivedita, et al.
Publicado: (2020) -
Prudent public health intervention strategies to control the coronavirus disease 2019 transmission in India: A mathematical model-based approach
por: Mandal, Sandip, et al.
Publicado: (2020) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010) -
Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)